🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

203+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 203 recruiting trials for “combined-hepatocellular-carcinoma-and-cholangiocarcinoma

Phase 1RecruitingNCT06546969

Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer

👨‍⚕️ Jason Molitoris, MD, PhD, University of Maryland Medical Center / Maryland Proton Treatment Center📍 2 sites📅 Started Oct 2024View details ↗
NARecruitingNCT06689670

Needle-based Percutaneous Ablation of Liver Tumors.

👨‍⚕️ Fatih Selcukbiricik, MD, Koc University Hospital📍 1 site📅 Started Oct 2024View details ↗
NARecruitingNCT06718153

Immunohistochemical Algorithm for the Diagnosis and Classification of Hepatocellular Carcinomas With TERT, TP53 and CTNNB1 Mutation

👨‍⚕️ Francesco Vasuri, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 1 site📅 Started Oct 2024View details ↗
Phase 1, PHASE2RecruitingNCT06730009

Phase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients

👨‍⚕️ Stanley Chang, PhD, Medigen Biotechnology Corporation📍 1 site📅 Started Oct 2024View details ↗
Phase 4RecruitingNCT06353126

DEB-TACE Prior to Liver Transplantation in the Treatment of HCC

👨‍⚕️ Jianjun Zhang, MD, RenJi Hospital📍 1 site📅 Started Oct 2024View details ↗
EARLY_Phase 1RecruitingNCT06418659

A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients

👨‍⚕️ Wei-Fen Xie, M.D., Shanghai Changzheng Hospital📍 1 site📅 Started Oct 2024View details ↗
RecruitingNCT06569498

Neoadjuvant Triple Therapy for Resectable HCC

🏥 Fujian Provincial Hospital📍 6 sites📅 Started Sep 2024View details ↗
RecruitingNCT06602011

Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)

🏥 Fujian Provincial Hospital📍 6 sites📅 Started Sep 2024View details ↗
RecruitingNCT06648057

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

👨‍⚕️ Hong Jae Chon, MD. PhD, CHA University📍 1 site📅 Started Sep 2024View details ↗
Phase 2RecruitingNCT06607276

Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE

🏥 The First Affiliated Hospital with Nanjing Medical University📍 4 sites📅 Started Sep 2024View details ↗
RecruitingNCT06777628

Immunophenotype of PBMC to Early Predict Response to Immunotherapy in Hepatocellular Carcinoma

👨‍⚕️ Laura Gramantieri, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 1 site📅 Started Sep 2024View details ↗
Phase 1RecruitingNCT06487559

A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

👨‍⚕️ ABBVIE INC., AbbVie📍 11 sites📅 Started Sep 2024View details ↗
Phase 3RecruitingNCT05744219

Improved Recovery by Iron Following Surgery With Blood Loss, the IRIS-trial

🏥 Jon Unosson📍 1 site📅 Started Sep 2024View details ↗
RecruitingNCT06718257

Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma

👨‍⚕️ Weilin Wang, PHD, Department of Hepatobiliary and Pancreatic Surgery, Second Affiliated Hospital, School of Medicine, Zhejiang University📍 1 site📅 Started Sep 2024View details ↗
Phase 2RecruitingNCT06852287

Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer

🏥 Tianjin Medical University Cancer Institute and Hospital📍 1 site📅 Started Sep 2024View details ↗
RecruitingNCT07101237

An Exploratory Study on Developing an Integrated Approach Combining Multimodal Imaging and Multi-omics Characterization of Tumor Heterogeneity for Precision Diagnosis and Treatment Optimization in Liver Cancer.

🏥 Peking Union Medical College Hospital📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT07303712

Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90

👨‍⚕️ Sirish Kishore, MD, VA Palo Alto Health Care System📍 1 site📅 Started Aug 2024View details ↗
Phase 2RecruitingNCT05733598

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

👨‍⚕️ May Cho, MD, Replimune Inc.📍 11 sites📅 Started Aug 2024View details ↗
Phase 2RecruitingNCT06309485

Phase 2 Study of WGI-0301 for Advanced HCC

🏥 Zhejiang Haichang Biotech Co., Ltd.📍 4 sites📅 Started Jul 2024View details ↗
RecruitingNCT07291063

Anti-PD-1/PD-L1 Antibodies Plus Gemcitabine and Cisplatin for Advanced CCA

🏥 Shanghai Zhongshan Hospital📍 1 site📅 Started Jul 2024View details ↗
← PreviousPage 4 of 11Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →